Skip to main content
Canadian Medical Association Journal logoLink to Canadian Medical Association Journal
. 1964 Aug 15;91(7):315–318.

Clinical Experience with a New Diuretic, Triamterene, in Congestive Heart Failure

S T Laufer, R N Mahabir
PMCID: PMC1927484  PMID: 14180540

Abstract

Triamterene therapy was evaluated in 35 patients with congestive heart failure over a period of two and one-half years. The parameters used were: clinical assessment; daily 24-hour urine sodium, potassium, chloride, and total volume; bi-weekly serum sodium, potassium, chloride, uric acid, and SGOT; hemogram, and BUN.

Triamterene is a moderately potent diuretic and natriuretic, with the added desirable property of potassium conservation. It acts synergistically with spironolactone and not only potentiates the effects of hydrochlorothiazide but greatly minimizes its kaluretic effect.

It is particularly useful in patients in whom cardiac arrhythmias are associated with digitalis intoxication or with inadvertently induced hypokalemia. Its main therapeutic value, used either alone or in combination with other diuretics, is in the longterm management of chronic edema, especially in certain patients refractory to the currently used diuretics.

No significant undesirable side effects were noted.

Full text

PDF
315

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BABA W. I., TUDHOPE G. R., WILSON G. M. Triamterene, a new diuretic drug. I. Studies in normal men and in adrenalectomized rats. Br Med J. 1962 Sep 22;2(5307):756–760. doi: 10.1136/bmj.2.5307.756. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. CATTELL W. R., HAVARD C. W. Diuretic action of triamterene in man. Br Med J. 1962 Nov 24;2(5316):1362–1366. doi: 10.1136/bmj.2.5316.1362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. CROSLEY A. P., Jr, RONQUILLO L. M., STRICKLAND W. H., ALEXANDER F. Triamterene, a new natruretic agent. Preliminary observations in man. Ann Intern Med. 1962 Feb;56:241–251. doi: 10.7326/0003-4819-56-2-241. [DOI] [PubMed] [Google Scholar]
  4. DONNELLY R. J., TURNER P., SOWRY G. S. Clinical trial of new oral diuretic-SKF 8542. Lancet. 1962 Feb 3;1(7223):245–247. doi: 10.1016/s0140-6736(62)91192-3. [DOI] [PubMed] [Google Scholar]
  5. ROWE G. G., AFONSO S., CASTILLO C. A., LOWE W. C., CRUMPTON C. W. Systemic and coronary hemodynamic effects of triamterene (2,4,7 triamino-6-phenyl pteridine) (27410). Proc Soc Exp Biol Med. 1962 May;110:27–29. doi: 10.3181/00379727-110-27410. [DOI] [PubMed] [Google Scholar]
  6. SHALDON S., RYDER J. A. Use of a pteridine diuretic (tri-amterene) in treatment of hepatic ascites. Br Med J. 1962 Sep 22;2(5307):764–767. doi: 10.1136/bmj.2.5307.764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. ZIMMERMAN H. B., GENTSCH K. W., GALE A. H. The action of potassium on the atrioventricular node in digitalized patients. Dis Chest. 1963 Apr;43:377–381. doi: 10.1378/chest.43.4.377. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES